For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Attruby represents a significant advancement . These groundbreaking therapies stabilize the transthyretin protein, slowing its destructive build-up and lessening the burden of the disease . People are now experiencing benefit